Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Multimodality Imaging in the Evaluation of Heart Failure and Surgical Transplant Planning of Patients with Adult Congenital Heart Disease.

Cardiac electrophysiology clinics·2026
Same author

Nebulized Treprostinil in Mechanically Ventilated Children.

Pediatric pulmonology·2025
Same author

Pulmonary Embolism Center of Excellence: Putting It All Together.

Cardiac electrophysiology clinics·2025
Same author

Association Between Bicuspid Aortic Valve and Main Pulmonary Artery Dilation in Adult Patients.

JACC. Advances·2025
Same author

Summary for Clinicians: Clinical Practice Guideline on Interventional Strategies for Children with Progressive Pulmonary Hypertension Despite Optimal Therapy.

Annals of the American Thoracic Society·2025
Same author

Shaping cardiac diagnostics: The role of myocardial tissue mapping in unraveling ring-like fibrosis.

Cardiology journal·2025

Related Experiment Video

Updated: Jun 19, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Recent Advances in Pulmonary Hypertension Management.

Sarah P Cohen1, Alexandria L Miller2, Saurabh Rajpal2

  • 1Division of Pulmonary, Critical Care & Sleep Medicine, Department of Internal Medicine, Davis Heart and Lung Research Institute, The Ohio State University School of Medicine, 241 West 11th Avenue Suite 5000, Columbus, OH 43210, USA; Division of Pulmonary Medicine, Department of Pediatrics, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USA.

Heart Failure Clinics
|June 17, 2026
PubMed
Summary
This summary is machine-generated.

Pulmonary arterial hypertension (PAH) management has advanced, improving outcomes. However, significant morbidity and mortality persist, necessitating personalized risk stratification and therapies for better patient care.

Keywords:
Pulmonary arterial hypertensionRisk stratificationTherapies

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Related Experiment Videos

Last Updated: Jun 19, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

Area of Science:

  • Cardiology
  • Pulmonology
  • Medical Research

Background:

  • Pulmonary hypertension (PH), particularly pulmonary arterial hypertension (PAH), has seen substantial management progress over the past 30 years.
  • Recent diagnostic, risk stratification, and therapeutic advancements have led to improved patient outcomes in PAH.
  • Despite progress, patients with PAH still face considerable morbidity and mortality.

Purpose of the Study:

  • To highlight the advancements in PAH management.
  • To underscore the ongoing challenges of morbidity and mortality in PAH patients.
  • To advocate for future research focused on individualized patient factors.

Main Methods:

  • Review of recent advancements in PAH diagnosis.
  • Analysis of current risk stratification models in PAH.
  • Evaluation of contemporary treatment strategies for PAH.

Main Results:

  • Significant improvements in PAH management over three decades.
  • Enhanced diagnostic and therapeutic approaches have positively impacted outcomes.
  • Persistent high rates of morbidity and mortality remain a critical issue in PAH.

Conclusions:

  • Continued research is essential for developing advanced risk stratification models.
  • Future therapies must incorporate individualized patient-specific factors for optimal PAH management.
  • Further efforts are needed to reduce the significant morbidity and mortality associated with PAH.